These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 25397556)

  • 41. Efficacy and improvement of lipid profile after switching to rilpivirine in resource limited setting: real life clinical practice.
    Gatechompol S; Avihingsanon A; Apornpong T; Han WM; Kerr SJ; Ruxrungtham K
    AIDS Res Ther; 2019 Apr; 16(1):7. PubMed ID: 30953533
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study.
    Gazaignes S; Resche-Rigon M; Gatey C; Yang C; Denis B; Fonsart J; Desseaux K; Guionie M; Rozenbaum W; Delaugerre C; Molina JM
    Antivir Ther; 2016; 21(4):329-36. PubMed ID: 26566057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    Allavena C; Dailly E; Reliquet V; Bonnet B; Pineau S; André-Garnier E; Boutoille D; Bouquié R; Raveleau A; Bouchez S; Billaud E; Raffi F
    J Antimicrob Chemother; 2014 Oct; 69(10):2804-8. PubMed ID: 24907142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines.
    Colombo GL; Di Matteo S; Antinori A; Medaglia M; Murachelli S; Rizzardini G
    Clinicoecon Outcomes Res; 2013 Oct; 5():489-96. PubMed ID: 24124383
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
    Lamorde M; Walimbwa S; Byakika-Kibwika P; Katwere M; Mukisa L; Sempa JB; Else L; Back DJ; Khoo SH; Merry C
    J Antimicrob Chemother; 2015 May; 70(5):1482-6. PubMed ID: 25652748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nuke-sparing regimens as a main simplification strategy and high level of toxicity resolution after antiretroviral switch: the SWITCHART Study.
    Carrero-Gras A; Antela A; Muñoz-Rodríguez J; Díaz-Menéndez M; Viciana P; Torrella-Domingo A; Sanz-Moreno J; Téllez-Molina MJ; Moreno J; Hernández-Quero J; Pérez-Hernández IA; Domingo-Pedrol P
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19819. PubMed ID: 25397563
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study.
    Si-Ahmed SN; Pradat P; Zoutendijk R; Buti M; Mallet V; Cruiziat C; Deterding K; Dumortier J; Bailly F; Esteban R; Wedemeyer H; Janssen HL; Zoulim F
    Antiviral Res; 2011 Oct; 92(1):90-5. PubMed ID: 21767570
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized, crossover, double-blind, placebo-controlled trial to assess the lipid lowering effect of co-formulated TDF/FTC.
    Santos JR; Saumoy M; Curran A; Bravo I; Navarro J; Estany C; Podzamczer D; Ribera E; Negredo E; Clotet B; Paredes R
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19550. PubMed ID: 25394057
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice.
    Costarelli S; Cozzi-Lepri A; Lapadula G; Bonora S; Madeddu G; Maggiolo F; Antinori A; Gori A; D'Arminio-Monforte A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19571. PubMed ID: 25394078
    [TBL] [Abstract][Full Text] [Related]  

  • 52. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.
    Palacios R; Mayorga M; Pérez-Hernández IA; Rivero A; Arco AD; Lozano F; Santos J;
    J Int Assoc Provid AIDS Care; 2016 May; 15(3):189-93. PubMed ID: 26858314
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study.
    Neukam K; Espinosa N; Merino D; Rivero-Juárez A; Carrero A; Ríos MJ; Ruiz-Morales J; Gómez-Berrocal A; Téllez F; Díaz-Menéndez M; Collado A; Pérez-Camacho I; Delgado-Fernández M; Vera-Méndez F; Pineda JA
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19631. PubMed ID: 25394135
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort.
    Di Biagio A; Cozzi-Lepri A; Prinapori R; Angarano G; Gori A; Quirino T; De Luca A; Costantini A; Mussini C; Rizzardini G; Antinori A; Monforte AD;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19825. PubMed ID: 25397569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
    Saumoy M; Ordoñez-Llanos J; Martínez E; Barragán P; Ribera E; Bonet R; Knobel H; Negredo E; Loncá M; Curran A; Gatell JM; Podzamczer D;
    Antivir Ther; 2011; 16(4):459-68. PubMed ID: 21685533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reasons, Efficacy and Safety of Switching to Dolutegravir-Based Regimens Among Virologically Suppressed PLWH: A Retrospective Cohort Study of 96 Weeks.
    Deng M; Chen N; Lao X; Wang X; Fu J; Xing L; Zhao H
    Infect Drug Resist; 2024; 17():1571-1582. PubMed ID: 38681898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study).
    Fabbiani M; Mondi A; Colafigli M; D'Ettorre G; Paoletti F; D'Avino A; Ciccarelli N; Sidella L; Murri R; Fortuna S; Vullo V; Cauda R; De Luca A; Di Giambenedetto S
    Scand J Infect Dis; 2014 Jan; 46(1):34-45. PubMed ID: 24161018
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Switching Tenofovir/Emtricitabine/Efavirenz (TDF/FTC/EFV) to TDF/FTC/Rilpivirine vs Continuing TDF/FTC/EFV in HIV-Infected Patients With Virological Suppression: A Randomized Controlled Trial.
    Wiriyatanakorn S; Sungkanuparph S
    Open Forum Infect Dis; 2019 Jul; 6(7):ofz297. PubMed ID: 31341931
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of Rilpivirine-Based Regimens as Switch Therapy From Nevirapine-Based Regimens in Human Immunodeficiency Virus-Infected Patients With Virological Suppression: A Randomized Controlled Trial.
    Petchkum P; Sungkanuparph S; Kiertiburanakul S; Phuphuakrat A
    Open Forum Infect Dis; 2019 Apr; 6(4):ofz155. PubMed ID: 31041351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.